Protein expression in Down syndrome brain

Amino Acids

Volumn 21, Issue 4, 2001, Pages 331-361

  Engidawork, E ^a   Lubec, G ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Apoptosis; Chromosome 21; Down syndrome; Fetal brain; Neurodevelopment; Oxidative stress; Protein expression

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CARRIER PROTEIN; CASPASE; CASPASE INHIBITOR; CELL ADHESION MOLECULE; CHAPERONE; CHROMOSOME PROTEIN; COPPER ZINC SUPEROXIDE DISMUTASE; CYTOKINE; DEOXYRIBONUCLEOPROTEIN; NEUROTRANSMITTER RECEPTOR; NEUROTROPHIC FACTOR; PEROXIREDOXIN; PROTEIN BCL 2; PROTEIN KINASE; PROTEIN S 100; TRANSCRIPTION FACTOR;

APOPTOSIS; CHROMOSOME 21; DOWN SYNDROME; GENE DOSAGE; GENE EXPRESSION REGULATION; HUMAN; NEUROPATHOLOGY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

ANTIOXIDANTS; APOPTOSIS; BRAIN; CELL ADHESION MOLECULES; CYTOKINES; DOWN SYNDROME; HUMANS; MOLECULAR CHAPERONES; NERVE GROWTH FACTORS; NEUROTRANSMITTER AGENTS; PROTEINS; SUPEROXIDE DISMUTASE;

EID: 0035659240     PISSN: 09394451     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007260170001     Document Type: Review

References (185)

1. Roles of molecular chaperones in cytoplasmic protein folding
2. Inflammation and Alzheimer's disease
3. Gene encoding the β subunit of S100 protein is on chromosome 21. Implications for Down syndrome
4. Human ICE/CED-3 proteases nomenclature
5. Morphological and biochemical assessment of DNA damage and apoptosis in Down syndrome and Alzheimer's disease, and effect of postmortem tissue archival on TUNEL
6. Lipid peroxidation and superoxide dismutase-1 and glutathione peroxidase activities in trisomy 16 fetal mice and human trisomy 21 fibroblast
7. 10 Years of genomics, chromosome 21, and Down syndrome
8. Excessive glutamate receptor 1 immunreactivity in adult Down syndrome brains
9. Developmental changes in the expression of amyloid precursor protein in Down syndrome brain
10. Development of the nervous system
11. Alzheimer's disease as a disorder of mechanisms underlying structural brain self-reorganization
12. S100β and serotonin: A possible astrocytic-neuronal link to neuropathology of Alzheimer's disease
13. Expression of Alzheimer's disease related proteins during development in Down syndrome
14. S100β stimulates calcium fluxes in glia and neuronal cells
15. Protein structure in receptor classification
16. Fetal human brain exhibits a prenatal peak in density of serotonin 5-HT1A receptors
17. CD95-CD95L: Can the brain learn from the immune system
18. Growth and development of the brain in Down syndrome
19. Cell surface trafikking of Fas: A rapid mechanism of p53 mediated apoptosis
20. Cytokines and inflammatory proteins in Alzheimer's disease
21. Decreased cyclin dependent kinase in brains of patients with Down syndrome
22. Neurochemical correlates of dementia severity in Alzheimer's disease: Relative importance of cholinergic deficits
23. The metabotropic gluatmate agonist 1S, 3R-ACPD stimulates and modulates NMDA receptor mediated excitotoxicity in organotypic hippocampal slice cultures
24. Chromosome localization of murine interleukin-1 α and β genes
25. p75 NTR and the concept of cellular dependence: Seeing how the other half die
26. Superoxide dismutase, glutathione peroxidase and lipoperoxidation in Down's syndrome fetal brain
27. Neuronal maturation in fetal brain in Down syndrome
28. Apoptosis and increased generation of active oxygen species in Down syndrome neurons in vitro
29. Cholinergic agonists and interleukin-1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor
30. Identification and molecular characterization of unc-33-like phosphoprotein (Ulip), a putative mammalian homolog of the axonal guidance associated unc-33 gene product
31. Neuropathology of Down syndrome
32. Relationships between neuronal death and the cellular redox status. Focus on the developing nervous system
33. Age related changes in antioxidant enzymes and lipid peroxidation in brains of control and transgenic mice overexpressing cooper-zinc superoxide dismutase
34. Cloning and sequencing of thiol-specific antioxidants from mammalian brain: Alkyl hydroperoxide reductase and thiol-specific antioxidants define a large family of antioxidant enzymes
35. Isoforms of mammalian peroxiredoxin that reduce peroxides in presence of thioredoxin
36. Evidence for the relation of herpes simplex virus type 1 to Down syndrome and Alzheimer's disease
37. Decreased protein levels of stathmin in adult brains with Down syndrome and Alzheimer's disease
38. The cell death machine
39. Enhanced DNA repair in lymphocytes of Down syndrome patients: The influence of zinc nutritional supplementation
40. Amino acid sequence of the triple helical domain of the human collagen type VI
41. SNAPs. A family of NSF attachment proteins involved in intracellular membrane fusion in animals and yeast
42. Caspases: The executioners of apoptosis
43. Activation of cell cycle associated proteins in neuronal death: A mandatory or dispensable path?
44. The neurobiologic consequences of Down syndrome
45. Dissecting the pathways to death
46. Reactive oxygen species and their contribution to pathology in Down syndrome
47. Molecular abnormalities of the brain in Down syndrome: Relevance to Alzheimer's neurodegeneration
48. p53 and CD95 associated apoptosis in neurodegenerative diseases
49. Cell adhesion molecules: Implications for molecular histology
50. Molecular chaperones, ten years
51. β-amyloid precursor protein, Ets-2, and collagen alpha 1 (VI) chain precursor, encoded on chromosome 21 are not overexpressed in fetal Down syndrome: Further evidence against gene dosage effect
52. Unaltered expression of Fas (CD95/APO-1), caspase-3, Bcl-2, and annexins inbrains of fetal Down syndrome: Evidence against increased apoptosis
53. Selective upregulation of the ubiquitin-proteasome proteolytic pathway proteins, proteasome zeta and isopeptidase T in fetal Down syndrome
54. Changes in nicotinic acetylcholine receptor subunits expression in brain of patient with Down syndrome and Alzheimer's disease
55. Expression of apoptosis related proteins: RAIDD, ZIP kinase, Bim/BOD, p21, Bax, Bcl-2 and NF-κB in brains of patients with Down syndrome
56. Expression of Apoptosis related proteins in brains of patients with Alzheimer's disease
57. Alteration of caspases and apoptosis-related proteins in brains of patients with Alzheimer's disease
58. Down syndrome
59. Down syndrome
60. A matter of life and cell death
61. Increased steady state mRNA levels of DNA-repair genes XRCC1, ERCC2 and ERCC3 in brain of patients with Down syndrome
62. Activated astrocytes in areas of kainate-induced neuronal injury upregulate the expression of the metabotropic glutamate receptors 2/3 and 5
63. Increased levels of 14-3-3 gama and epsilon proteins in brain of patients with Alzheimer's disease and Down syndrome
64. A family of serine proteases expressed exclusively in myleomonocytic cells specifically process the NF-κB subunit p65 in vitro and may impair HIV replication in these cells
65. 14-3-3 Proteins: Structure, function, and regulation
66. DSCR1 overexpressed in Down syndrome, is an inhibitor of calcineurin mediated signaling
67. Reversible impairment of long-term potentiation in transgenic Cu/Zn-SOD mice
68. Dietary increase in serotonin reduces self-injurious behavior in a Down syndrome adult
69. Serotonergic treatment for aggression in a Down syndrome adult showing signs of Alzheimer's disease
70. Treatment of functional decline in adults with Down syndrome using selective serotonin reuptake inhibitor drugs
71. Alzheimer like neurotransmitter deficits in adult Down syndrome brain tissue
72. Interleukin-1 regulates synthesis of amyloid beta protein precursor mRNA in human endothelial cells
73. Collapsin induced growth cone collapse by an intracellular protein related to unc-33
74. Decreased levels of synaptosomal associated protein 25 in the brain of patient with Down syndrome and Alzheimer's disease
75. The expression of the transcription factor ets-2 in brain of patients with Down syrdrome evidence against the overexpression-gene dosage hypothesis
76. Evidence against the current hypothesis of gene dosage effects of trisomy 21: ETS-2 encoded on chromosome 21 is not overexpressed in hearts of patient with Down syndrome
77. Life-long overexpression of S100β in Down syndrome: Implications for Alzheimer's pathogenesis
78. Brain interleukin 1 and S100β immunoreactivity are elevated in Down syndrome and Alzheimer's disease
79. Nuclear kappa B/Rel proteins: A point of convergence of signaling pathways relevant in neuronal function and dysfunction
80. Increased protein levels of serotonin transporter in frontal cortex of patients with Down syndrome
81. Antioxidant proteins in fetal brain: Superoxide dismutase-1 (SOD-1) is not overexpressed in fetal Down syndrome
82. Alteration of caspases and their regulatory proteins in brains of Down syndrome
83. Superoxide dismutase, SOD1 encoded on chromosome 21, but not SOD2 is overexpressed in brains of patient with Down syndrome
84. Cell-specific regulation of oncogene-responsive sequences of the c-fos promoter
85. Cellular processing of β amyloid precursor protein and the genesis of amyloid beta peptide
86. Novel gene family defined by human dihydropyrimidinase and three related proteins with differential tissue distribution
87. p53 from inductive signal to cellular effect
88. The DNA sequence of human chromosome 21
89. Evidence against the involvement of reactive oxygen species in the pathogenesis of neuronal death in Down syndrome and Alzheimer's disease
90. Mechanisms of complex transcriptional regulation: Implications for brain development
91. Expression of DNA excision repair cross complementing proteins p80 and p89 in brain of patients with Down syndrome and Alzheimer's disease
92. Down syndrome with duplication of a region of chromosome 21 containing SOD1 gene without detectable karyotype abnormality
93. Oxidative stress and neural dysfunction in Down syndrome
94. Age related loss of the AMPA receptor subunits GluR2/3 in the human nucleus basalis of Meynert
95. RICK, a novel protein kinase containing a caspase recruitment domain, interacts with CLARP and regulates CD95-mediated apoptosis
96. Further characterization of the three polypeptide chains of bovine and human short-chain collagen (intima collagen)
97. Regulatory role for a novel human thioredoxin peroxidase in NF-kappaB activation
98. Serum interleukin-6 levels correlate with the severity of dementia in Down syndrome and Alzheimer's disease
99. Inhibition of NF-κB potentiates amyloid β peptide mediated neuronal apoptosis
100. The precursor of Alzheimer's amyloid A4 protein resembles a cell surface receptor
101. Characterization of mammalian peroxiredoxin that contain one conserved cysteine
102. Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factor-alpha
103. Protein levels of human peroxiredoxin subtypes in brains of patients with Alzheimer's disease and Down syndrome
104. Decreased levels of ARPP-19 and PKA in brains of Down syndrome and Alzheimer's disease
105. Neuroendocrine-specific protein C, a marker of neuronal differentiation, is reduced in brain of patients with Down syndrome and Alzheimer's disease
106. Targeting small Aβ oligomers: The solution to an Alzheimer's disease conundrum
107. Purification and characterization of a neurite extension factor from bovine brain
108. Down syndrome phenotypes: The consequences of chromosomal imbalance
109. Mechanisms of programmed cell death in the developing brain
110. Decreased transcription factor jun D in brains of patients with Down syndrome
111. Amyloid precursor protein processing is stimulated by metabotropic glutamate receptors
112. The NG-2 chondrotin sulfate proteoglycan: A multifunctional proteoglycan associated with immature cells
113. Cytochrome c and dATP dependent formation of Apaf-1/caspase-9 complex initiates an apoptosis cascade
114. Down syndrome patients start early prenatal life with normal cholinergic, monoaminergic, and serotonergic innervation
115. Expression of the dihydropyrimidinase related protein-2 (DRP-2) in Down syndrome and Alzheimer's disease brain is downregulated at the mRNA level and dysregulated at the protein level
116. The pathological association between Down syndrome and Alzheimer's disease
117. Increased S100β neurotrophic activity in Alzheimer's temporal lobe
118. Roles of nuclear kappaB in neuronal survival and plasticity
119. Regulation of amyloid precursor protein cleavage
120. TOAD-64 a gene expressed early in neonatal differentiation in the rat, is related to unc-33, a C.elegans gene involved in axon outgrowth
121. Bidirectional regulation of neurite elaboration by alternatively spliced metabotropic glutamate receptor 5 (mGluR5) isoforms
122. Apoptosis in neurodegenerative disorders
123. Glial cytokines in Alzheimer's disease
124. Apoptosis related protein expression in the hippocampus in Alzheimer's disease
125. Caspase-12 mediates endoplasmic reticulum specific apoptosis and cytotoxicity by amyloid β
126. Alzheimer's disease: A dysfunction of the amyloid precursor protein
127. Induction of cyclo-oxygenase 2 in brains of patient's with Down syndrome and dementia of the Alzheimer type: Specific localization in affected neurons and axons
128. The upregulation of metabotropic receptor 5 (mGluR5) in Down syndrome brain
129. Peroxiredoxin VI is a secretale protein with heparin binding properties under reduced conditions
130. Down's syndrome: Upregulation of β-amyloid protein precursor and tau mRNAs and their defective coordination
131. Interaction partners of Dlk/ZIP kinase: Co-expression of Dlk/ZIP kinase and Par-4 results in cytoplasmic retention and apoptosis
132. No significant effect of monosomy for distal 21q22.3 on the Down syndrome phenotype in mirror duplication of chromosome 21
133. Conversion of p35 to p25 deregulates cdk5 activity and promotes neurodegeneration
134. Synaptic development in the human fetus: A morphometric analysis of normal and Down syndrome neocortex
135. Aberrant expression of signaling related proteins 14-3-3 gama and RACK-1 in fetal Down syndrome brain (trisomy 21)
136. Organizational and chromosomal assignment of two human PAG gene loci: PAGA encoding a functional gene and PAGB a processed pseudogene
137. Amino acid neurotransmitter deficits in adult Down syndrome brain tissue
138. Human DNA repair genes
139. The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling
140. A protein encoded within the Down syndrome critical region is enriched in striated muscles and inhibits calcineurin signaling
141. Mechanisms of apoptotic cell death
142. Amyloid A4 protein and its precursor in Down syndrome and Alzheimer's disease
143. The developmental and aging changes of Down syndrome cell adhesion molecule expression in normal and Down syndrome brain
144. Aberrant expression of Bcl-2 gene family in Down syndrome brains
145. Bcl-2 proteins as ion channels
146. Similar deficits of central histaminergic system in patients with Down syndrome and Alzheimer's disease
147. Vesicular neurotransmitter transporters
148. Genetic dissociation of structural and functional components of synaptic plasticity. II Fascicilin II controls presynaptic structural plasticity
149. Neuronal apoptosis inhibitory protein (NAIP)-like immunoreactivity in brains of adult with Down syndrome
150. Apoptosis associated proteins p53 and APO-1/FAS (CD95) in brains of adult patients with Down syndrome
151. Serotonin in brains of adult patients with Down syndrome
152. Effects of transdermal nicotine on cognitive performance in Down syndrome
153. Amyloid β protein and the genetics of Alzheimer's disease
154. The Down syndrome critical region
155. Thioredoxin peroxidase (natural killer enhancing factor) regulation of activator protein-1 function in endothelial cells
156. Human brain S100 beta and S100 beta mRNA expression increases with age: Pathogenic implications for Alzheimer's disease
157. Glial-neuronal interaction in Alzheimer's disease: Progressive association of IL-1α+ microglia and S100β+ astrocytes with neurofibrillary tangle stage
158. 14-3-3 Proteins in neuronal development and function
159. Molecular biology of nurotransmitter release
160. Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease
161. Baculovirus mediated expression of neurotransmitter transporters
162. Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down's syndrome
163. Functional identification of vesicular monoamine and acetylcholine transporters
164. Fas ligand induced c-Jun kinase activation in lymphoid cells requires extensive receptor aggregation but is independent of DAXX, and Fas-mediated cell death does not involve DAXX, RIP or RAIDD
165. Bcl-2 expression regulates cell sensitivity to S100β mediated apoptosis
166. The c-ets proto-oncogene encode transcription factors that cooperate with c-Fos and c-Jun for transcriptional activation
167. Cloning and chromosomal localization of human genes encoding the three chains of type VI collagen
168. Aberrant expression of dihydropyrimidinase related protein-2, -3, and -4 in fetal Down syndrome
169. Fetal life in Down syndrome starts with normal neuronal density but impaired dendritic spines and synaptosomal structures
170. Reduction of nucleoside diphosphate kinase B, Rab GDP-dissociation inhibitor beta, and histidine triad nucleotide binding protein in fetal Down syndrome brain
171. Caspases and neurodegeneration: On the cutting edge of new therapeutic approaches
172. Stimulation of astroglial 5-HT1A receptors releases the serotonergic growth factor, protein S100, and alters astroglial morphology
173. The cholinergic deficit in Alzheimer's disease
174. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down syndrome
175. DSCAM: A novel member of the immunoglobulin superfamily maps in a Down syndrome region and is involved in the development of the nervous system
176. Regional brain 5-hydroxytryptamine levels are reduced in senile Down syndrome as in Alzheimer's disease
177. p25 protein in neurodegeneration
178. Synaptosomal proteins, beta soluble N-ethylmaleimide sensitive factor attachment protein (β-SNAP) and synaptotagmin I in brain of patients with Down syndrome and Alzheimer's disease
179. Changes of voltage dependent anion selective channel proteins VDAC1 and VDAC2 brain levels in patients with Alzheimer's disease and Down syndrome
180. Expression of chaperone proteins in cerebral cortex of the fetus with Down syndrome; dysregulation of T-complex protein 1
181. Differential expression of molecular chaperones in brains of patients with Down syndrome
182. Overexpression of Bcl-2 in transient abnormal myleopoiesis associated with Down syndrome
183. Synaptotagmin I is a high affinity receptor for clathrin AP-2: Implications for membrane recycling
184. Thioredoxin peroxidase is a novel inhibitor of apoptosis with a mechanism distinct from that of Bcl-2
185. Mouse peroxiredoxin V is a thioredoxin peroxidase that inhibits p53-induced apoptosis